Posted by Michael Wonder on 16 Jun 2023
Takeda and HUTCHMED announce marketing authorisation application of fruquintinib for previously treated metastatic colorectal cancer validated by the European Medicines Agency
15 June 2023 - Application Includes Data from Phase 3 FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (BSC) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colorectal Cancer.
Takeda and HUTCHMED today announced that the EMA has validated and accepted for regulatory review the marketing authorisation application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.
